US20070043033A1 - Unsolvated benzodiazepine compositions and methods - Google Patents
Unsolvated benzodiazepine compositions and methods Download PDFInfo
- Publication number
- US20070043033A1 US20070043033A1 US11/445,010 US44501006A US2007043033A1 US 20070043033 A1 US20070043033 A1 US 20070043033A1 US 44501006 A US44501006 A US 44501006A US 2007043033 A1 US2007043033 A1 US 2007043033A1
- Authority
- US
- United States
- Prior art keywords
- aliphatic chain
- branched
- saturated
- linear
- carbons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C(C2=NC([8*])C(=O)N([7*])C3=CC=CC=C32)C([4*])=C([3*])C([5*])=C1[2*].[6*]C Chemical compound [1*]C1=C(C2=NC([8*])C(=O)N([7*])C3=CC=CC=C32)C([4*])=C([3*])C([5*])=C1[2*].[6*]C 0.000 description 59
- HIJCSNHREFFOML-UHFFFAOYSA-N CN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21 Chemical compound CN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21 HIJCSNHREFFOML-UHFFFAOYSA-N 0.000 description 7
- NNDRZDJNKNZJBL-UHFFFAOYSA-N CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1O Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1O NNDRZDJNKNZJBL-UHFFFAOYSA-N 0.000 description 4
- KQGAUCCKIJVPPR-UHFFFAOYSA-N CC.CC.CC.CC.CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C Chemical compound CC.CC.CC.CC.CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C KQGAUCCKIJVPPR-UHFFFAOYSA-N 0.000 description 3
- YHSNFJFZKFKXPH-UHFFFAOYSA-N CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1 Chemical compound CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1 YHSNFJFZKFKXPH-UHFFFAOYSA-N 0.000 description 2
- YZSBJDZPTMYHPF-UHFFFAOYSA-N CC.CC.CC.CC.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C Chemical compound CC.CC.CC.CC.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C YZSBJDZPTMYHPF-UHFFFAOYSA-N 0.000 description 2
- DZZBQAJJRCWZES-UHFFFAOYSA-N CC.CC.CC.CC1=CC=CC=C1.C[W][W] Chemical compound CC.CC.CC.CC1=CC=CC=C1.C[W][W] DZZBQAJJRCWZES-UHFFFAOYSA-N 0.000 description 2
- YYDNBUBMBZRNQQ-UHFFFAOYSA-N CC1=CC=C(S(C)(=O)=O)C=C1 Chemical compound CC1=CC=C(S(C)(=O)=O)C=C1 YYDNBUBMBZRNQQ-UHFFFAOYSA-N 0.000 description 2
- YICAMJWHIUMFDI-UHFFFAOYSA-N CC(=O)NC1=CC=C(C)C=C1 Chemical compound CC(=O)NC1=CC=C(C)C=C1 YICAMJWHIUMFDI-UHFFFAOYSA-N 0.000 description 1
- IEYVZPFPYKFGAJ-UHFFFAOYSA-N CC(C)(C)C1=CC=C(Cl)C=C1.CC(C)(C)C1=CC=C(N=[N+]=[N-])C=C1.CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=CC=C1O.COC1=CC=C(C(C)(C)C)C=C1 Chemical compound CC(C)(C)C1=CC=C(Cl)C=C1.CC(C)(C)C1=CC=C(N=[N+]=[N-])C=C1.CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=CC=C1O.COC1=CC=C(C(C)(C)C)C=C1 IEYVZPFPYKFGAJ-UHFFFAOYSA-N 0.000 description 1
- LEZKRNYADGCOKN-UHFFFAOYSA-N CC(C)(C)C1=CC=C(N=[N+]=[N-])C=C1.CC(C)(C)C1=CC=C(O)C=C1.CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=CC=C1O.COC1=CC=C(C(C)(C)C)C=C1 Chemical compound CC(C)(C)C1=CC=C(N=[N+]=[N-])C=C1.CC(C)(C)C1=CC=C(O)C=C1.CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=CC=C1O.COC1=CC=C(C(C)(C)C)C=C1 LEZKRNYADGCOKN-UHFFFAOYSA-N 0.000 description 1
- XHEKYEXYOMFSMX-UHFFFAOYSA-N CC(C)(C)C1=CC=C(O)C=C1.CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=CC=C1O Chemical compound CC(C)(C)C1=CC=C(O)C=C1.CC1=CC(C(C)(C)C)=CC(C)=C1O.CC1=CC(C(C)(C)C)=CC=C1.CC1=CC(C(C)(C)C)=CC=C1O XHEKYEXYOMFSMX-UHFFFAOYSA-N 0.000 description 1
- SOJNZSKMAUISBT-UHFFFAOYSA-N CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1 Chemical compound CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1 SOJNZSKMAUISBT-UHFFFAOYSA-N 0.000 description 1
- LPLPGKUQOUQNFN-UHFFFAOYSA-N CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)CC1=CC=C(OC(F)(F)F)C=C1.CC(C)(C)CC1=CC=CC=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C Chemical compound CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)CC1=CC=C(OC(F)(F)F)C=C1.CC(C)(C)CC1=CC=CC=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C LPLPGKUQOUQNFN-UHFFFAOYSA-N 0.000 description 1
- DZXQIZHMIPZBOK-UHFFFAOYSA-N CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=CC=C1 Chemical compound CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=CC=C1 DZXQIZHMIPZBOK-UHFFFAOYSA-N 0.000 description 1
- WHVCQKHGBONLHB-UHFFFAOYSA-N CC.CC.CC.CC.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C Chemical compound CC.CC.CC.CC.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC(C2=CC=CC=C2)=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C WHVCQKHGBONLHB-UHFFFAOYSA-N 0.000 description 1
- WVRXJQRSVIKUET-UHFFFAOYSA-N CC.CC.CC.CC.CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C Chemical compound CC.CC.CC.CC.CC.CC(C)(C)C1=C(C2=CC=CC=C2)C=CC=C1.CC(C)(C)C1=CC=C(C2=CC=CC=C2)C=C1.CC(C)(C)C1=CC=C2C=CC=CC2=C1.CC(C)(C)C1=CC=CC2=C1C=CC=C2.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=C1.CC(C)(C)CC1=CC=C(C(C)(C)C)C=C1.CC(C)(C)CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C)C(CC(C)(C)C)=C1.CC1=CC=C(CC(C)(C)C)C=C1.CC1=CC=C(CC(C)(C)C)C=C1C.CC1=CC=C(CC(C)(C)C)C=C1C WVRXJQRSVIKUET-UHFFFAOYSA-N 0.000 description 1
- ZXUSWCYKFRSCAO-UHFFFAOYSA-N CC1=C(S(=O)(=O)N2CC3=C(C=CC=C3)N(CC3=CN=CN3)C(CCC3=CC=CC=C3)C2)C=C(Cl)C=C1.O=S(=O)(C1=CC=CS1)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1 Chemical compound CC1=C(S(=O)(=O)N2CC3=C(C=CC=C3)N(CC3=CN=CN3)C(CCC3=CC=CC=C3)C2)C=C(Cl)C=C1.O=S(=O)(C1=CC=CS1)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1 ZXUSWCYKFRSCAO-UHFFFAOYSA-N 0.000 description 1
- ZALDYSGZEJOLCW-UHFFFAOYSA-N CC1=CC(C)=C(O)C(C)=C1.CC1=CC=C(O)C(C)=C1 Chemical compound CC1=CC(C)=C(O)C(C)=C1.CC1=CC=C(O)C(C)=C1 ZALDYSGZEJOLCW-UHFFFAOYSA-N 0.000 description 1
- NJKQAGWWUCUFRN-UHFFFAOYSA-N CC1=CC=C(N2CCC(=O)N(C3=CC4=C(C=CC=C4)C=C3)C3=CC=C(O)C=C32)C=C1 Chemical compound CC1=CC=C(N2CCC(=O)N(C3=CC4=C(C=CC=C4)C=C3)C3=CC=C(O)C=C32)C=C1 NJKQAGWWUCUFRN-UHFFFAOYSA-N 0.000 description 1
- BBEUMTWVLMAZLI-UHFFFAOYSA-N CC1=CC=C(S(=O)(=O)N2CC3=C(C=CC=C3)N(CC3=CN=CN3)C(CCC3=CC=CC=C3)C2)C=C1.CC1=CC=C(S(=O)(=O)N2CC3=C(C=CC=C3)N(CC3=CNC(C)=N3)C(CCC3=CC=CC=C3)C2)C=C1.CS(=O)(=O)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1.O=S(=O)(C1=CC=C2C=CC=NC2=C1)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1.O=S(=O)(C1=CC=C2C=NC=CC2=C1)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1 Chemical compound CC1=CC=C(S(=O)(=O)N2CC3=C(C=CC=C3)N(CC3=CN=CN3)C(CCC3=CC=CC=C3)C2)C=C1.CC1=CC=C(S(=O)(=O)N2CC3=C(C=CC=C3)N(CC3=CNC(C)=N3)C(CCC3=CC=CC=C3)C2)C=C1.CS(=O)(=O)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1.O=S(=O)(C1=CC=C2C=CC=NC2=C1)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1.O=S(=O)(C1=CC=C2C=NC=CC2=C1)N1CC2=C(C=CC=C2)N(CC2=CN=CN2)C(CCC2=CC=CC=C2)C1 BBEUMTWVLMAZLI-UHFFFAOYSA-N 0.000 description 1
- VZYGEUZGYSCGFG-UHFFFAOYSA-N CC1=CC=C2C=C(=O)CC2=C1.CC1=CC=C2C=CNC2=C1.CC1=CC=C2[Y]=C(=O)CC2=C1.CNC1=CC=C(C)C=C1 Chemical compound CC1=CC=C2C=C(=O)CC2=C1.CC1=CC=C2C=CNC2=C1.CC1=CC=C2[Y]=C(=O)CC2=C1.CNC1=CC=C(C)C=C1 VZYGEUZGYSCGFG-UHFFFAOYSA-N 0.000 description 1
- DZVQCUAKZFRXNP-WXOGKORCSA-N CC1=CC=CC=C1.CCC1=C2/C=C\C=C/C2=CC=C1.CCC1=CC(C2=CC=CC=C2)=CC=C1.CCC1=CC=C(/C=C/C2=CC=CC=C2)C=C1.CCC1=CC=C(C(C)(C)C)C=C1.CCC1=CC=C(C2=CC=C(C(C)(C)C)C=C2)C=C1.CCC1=CC=C(C2=CC=C(C)C=C2)C=C1.CCC1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1.CCC1=CC=C(C2=CC=CC(C)=C2)C=C1.CCC1=CC=C(C2=CC=CC=C2)C=C1.CCC1=CC=C(C2=CC=CC=C2C)C=C1.CCC1=CC=C(C2=CC=CC=C2Cl)C=C1.CCC1=CC=C(CC2=CC=CC=C2)C=C1.CCC1=CC=C2/C=C\C=C/C2=C1.CCC1=CC=CC=C1.CCC1CNC2=C1C=CC=C2.CCC1CNC2=C1C=CC=C2.CCCC1=CC=CC=C1 Chemical compound CC1=CC=CC=C1.CCC1=C2/C=C\C=C/C2=CC=C1.CCC1=CC(C2=CC=CC=C2)=CC=C1.CCC1=CC=C(/C=C/C2=CC=CC=C2)C=C1.CCC1=CC=C(C(C)(C)C)C=C1.CCC1=CC=C(C2=CC=C(C(C)(C)C)C=C2)C=C1.CCC1=CC=C(C2=CC=C(C)C=C2)C=C1.CCC1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1.CCC1=CC=C(C2=CC=CC(C)=C2)C=C1.CCC1=CC=C(C2=CC=CC=C2)C=C1.CCC1=CC=C(C2=CC=CC=C2C)C=C1.CCC1=CC=C(C2=CC=CC=C2Cl)C=C1.CCC1=CC=C(CC2=CC=CC=C2)C=C1.CCC1=CC=C2/C=C\C=C/C2=C1.CCC1=CC=CC=C1.CCC1CNC2=C1C=CC=C2.CCC1CNC2=C1C=CC=C2.CCCC1=CC=CC=C1 DZVQCUAKZFRXNP-WXOGKORCSA-N 0.000 description 1
- NVPWDCLUDNDQLE-UHFFFAOYSA-N CC1=CC=CC=C1.CC[Y] Chemical compound CC1=CC=CC=C1.CC[Y] NVPWDCLUDNDQLE-UHFFFAOYSA-N 0.000 description 1
- RNEISXQIZHDGCI-UHFFFAOYSA-N CC1N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C2N(CC2=CC=C3C=CC=CC3=C2)C1=O Chemical compound CC1N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C2N(CC2=CC=C3C=CC=CC3=C2)C1=O RNEISXQIZHDGCI-UHFFFAOYSA-N 0.000 description 1
- BFYDZFLACRPCLW-UHFFFAOYSA-N CCCCCCN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21.NCCCCCN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21 Chemical compound CCCCCCN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21.NCCCCCN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)N=C(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21 BFYDZFLACRPCLW-UHFFFAOYSA-N 0.000 description 1
- JBINWXLJWVJZJL-UHFFFAOYSA-N CN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)CN(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21.CN1C(=O)C(CC2=CC=CC=C2C2=CC=CC=C2)C=N(C2=CC3=C(C=C2)NC(=O)N3)C2=CC(Cl)=CC=C21.CN1C(=O)C(CC2=CC=CC=C2C2=CC=CC=C2)C=N(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21 Chemical compound CN1C(=O)C(CC2=CC=C3C=CC=CC3=C2)CN(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21.CN1C(=O)C(CC2=CC=CC=C2C2=CC=CC=C2)C=N(C2=CC3=C(C=C2)NC(=O)N3)C2=CC(Cl)=CC=C21.CN1C(=O)C(CC2=CC=CC=C2C2=CC=CC=C2)C=N(C2=CC=C(O)C=C2)C2=CC(Cl)=CC=C21 JBINWXLJWVJZJL-UHFFFAOYSA-N 0.000 description 1
- GCJJQBPYGHJOMS-UHFFFAOYSA-N CN1C(=O)C(CC2=CC=CC(C3=CC=CC=C3)=C2)NC(=O)C2=C\C(Cl)=C/C=C\21 Chemical compound CN1C(=O)C(CC2=CC=CC(C3=CC=CC=C3)=C2)NC(=O)C2=C\C(Cl)=C/C=C\21 GCJJQBPYGHJOMS-UHFFFAOYSA-N 0.000 description 1
- QPUYECUOLPXSFR-UHFFFAOYSA-N Cc1cccc2c1cccc2 Chemical compound Cc1cccc2c1cccc2 QPUYECUOLPXSFR-UHFFFAOYSA-N 0.000 description 1
- WDQBPUSLLAKNDC-UHFFFAOYSA-N O=C1NC2=CC=C(Cl)C=C2C(C2=CC=C(O)C=C2)=NC1C1=CC=C2C=CC=CC2=C1 Chemical compound O=C1NC2=CC=C(Cl)C=C2C(C2=CC=C(O)C=C2)=NC1C1=CC=C2C=CC=CC2=C1 WDQBPUSLLAKNDC-UHFFFAOYSA-N 0.000 description 1
- LJQSCYGAAPSHDK-UHFFFAOYSA-N [AsH3].[O-]C([O-])O Chemical compound [AsH3].[O-]C([O-])O LJQSCYGAAPSHDK-UHFFFAOYSA-N 0.000 description 1
- ADJQAKCDADMLPP-STQMWFEESA-M [H][C@]([NH3+])(CCC(=O)N[C@@]([H])(CSCC(=O)NC1=CC=C([As](O)O)C=C1)C(=O)NCC(=O)[O-])C(=O)[O-] Chemical compound [H][C@]([NH3+])(CCC(=O)N[C@@]([H])(CSCC(=O)NC1=CC=C([As](O)O)C=C1)C(=O)NCC(=O)[O-])C(=O)[O-] ADJQAKCDADMLPP-STQMWFEESA-M 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/445,010 US20070043033A1 (en) | 2005-06-01 | 2006-06-01 | Unsolvated benzodiazepine compositions and methods |
US12/473,144 US7994313B2 (en) | 2005-06-01 | 2009-05-27 | Unsolvated benzodiazepine compositions and methods |
US13/188,234 US20120077805A1 (en) | 2005-06-01 | 2011-07-21 | Unsolvated benzodiazepine compositions and methods |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68634805P | 2005-06-01 | 2005-06-01 | |
US70410205P | 2005-07-29 | 2005-07-29 | |
US11/445,010 US20070043033A1 (en) | 2005-06-01 | 2006-06-01 | Unsolvated benzodiazepine compositions and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/473,144 Continuation US7994313B2 (en) | 2005-06-01 | 2009-05-27 | Unsolvated benzodiazepine compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070043033A1 true US20070043033A1 (en) | 2007-02-22 |
Family
ID=38006350
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/445,010 Abandoned US20070043033A1 (en) | 2005-06-01 | 2006-06-01 | Unsolvated benzodiazepine compositions and methods |
US12/473,144 Expired - Fee Related US7994313B2 (en) | 2005-06-01 | 2009-05-27 | Unsolvated benzodiazepine compositions and methods |
US13/188,234 Abandoned US20120077805A1 (en) | 2005-06-01 | 2011-07-21 | Unsolvated benzodiazepine compositions and methods |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/473,144 Expired - Fee Related US7994313B2 (en) | 2005-06-01 | 2009-05-27 | Unsolvated benzodiazepine compositions and methods |
US13/188,234 Abandoned US20120077805A1 (en) | 2005-06-01 | 2011-07-21 | Unsolvated benzodiazepine compositions and methods |
Country Status (7)
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070036854A1 (en) * | 1999-04-30 | 2007-02-15 | Glick Gary D | Therapeutic applications of pro-apoptotic benzodiazepines |
US20080064686A1 (en) * | 2006-04-27 | 2008-03-13 | The Regents Of The University Of Michigan | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof |
US20090093565A1 (en) * | 2007-10-04 | 2009-04-09 | Board Of Regents, The University Of Texas System | Bio-polymer and scaffold-sheet method for tissue engineering |
US7638624B2 (en) | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
US7851465B2 (en) | 2007-03-09 | 2010-12-14 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7994313B2 (en) | 2005-06-01 | 2011-08-09 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
US8088759B2 (en) | 2005-11-01 | 2012-01-03 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US8097612B2 (en) | 2006-06-09 | 2012-01-17 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US8188072B2 (en) | 2007-11-06 | 2012-05-29 | The Regents Of The University Of Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions |
US8324258B2 (en) | 2007-09-14 | 2012-12-04 | The Regents Of The University Of Michigan | F1F0-ATPase inhibitors and related methods |
US8497307B2 (en) | 2008-09-11 | 2013-07-30 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
US8604023B2 (en) | 2009-04-17 | 2013-12-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
US8673897B2 (en) | 2009-09-18 | 2014-03-18 | The Regents Of The University Of Michigan | Benzodiazepinone compounds and methods of treatment using same |
US8815845B2 (en) | 2009-11-17 | 2014-08-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3384635A (en) * | 1966-09-28 | 1968-05-21 | Sterling Drug Inc | 1, 4-benzodiazepine derivatives |
US3415814A (en) * | 1966-09-28 | 1968-12-10 | Sterling Drug Inc | 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione |
US3621828A (en) * | 1968-10-21 | 1971-11-23 | Ib Schreiner Hansen | Target projecting device with magazine indexing mechanism |
US4076823A (en) * | 1977-08-18 | 1978-02-28 | E. R. Squibb & Sons, Inc. | Triazolo-2,4-benzodiazepines |
US4110337A (en) * | 1973-03-09 | 1978-08-29 | Lipha, Lyonnaise Industrielle Pharmaceutique | Triazolobenzodiazepines |
US4495101A (en) * | 1983-04-28 | 1985-01-22 | American Home Products Corporation | Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives |
US4751223A (en) * | 1986-10-14 | 1988-06-14 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines |
US4898861A (en) * | 1987-03-26 | 1990-02-06 | Hoffmann-La Roche Inc. | Method for inhibiting the proliferation of tumor cells |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5041438A (en) * | 1989-10-30 | 1991-08-20 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with benzodiazepine compounds |
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5324726A (en) * | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
US5597915A (en) * | 1992-03-16 | 1997-01-28 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
US5776946A (en) * | 1995-08-28 | 1998-07-07 | Mcgeer; Patrick L. | Peripheral benzodiazepine receptor ligands as antiinflammatory agents |
US5861380A (en) * | 1994-11-21 | 1999-01-19 | Cortech, Inc. | Serine protease inhibitors-keto and di-keto containing ring systems |
US6004942A (en) * | 1995-08-30 | 1999-12-21 | The Regents Of The University Of California | Methods for treating arthritis by administering an apoptosis regulator |
US6080588A (en) * | 1995-05-18 | 2000-06-27 | The Regents Of The University Of Michigan | Therapeutic methods for benzodiazepine derivatives |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
US20010016583A1 (en) * | 1995-05-18 | 2001-08-23 | Gary D. Glick | Therapeutic application of pro-apoptotic benzodiazepines |
US6319931B1 (en) * | 1998-06-22 | 2001-11-20 | Centre National De Al Recherche Scientifique (Cnrs) | Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy |
US6506744B1 (en) * | 1999-07-13 | 2003-01-14 | Hoffmann-La Roche Inc. | Benzazepinone-derivatives |
US6767533B1 (en) * | 1998-11-17 | 2004-07-27 | Sanofi-Synthelabo | Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2457405A (en) | 1945-09-25 | 1948-12-28 | Monsanto Chemicals | Halo nitroparaffin modified aminoplasts |
US3261828A (en) | 1962-10-04 | 1966-07-19 | Hoffmann La Roche | 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds |
AT280290B (de) | 1967-11-24 | 1970-04-10 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen 1-Phenyl-4-alkyl-3H-1,4-benzodiazepin-2,5-[1H,4H]-dionen |
USRE30293E (en) | 1969-03-18 | 1980-06-03 | Knoll A.G. | Process for preparing 1,5-benzodiazepine-2-ones |
US4108852A (en) | 1969-03-18 | 1978-08-22 | Knoll Ag. | Process for preparing 1,5-benzodiazepine-2-ones |
CH559729A5 (US20070043033A1-20070222-C00111.png) | 1970-10-23 | 1975-03-14 | Hoechst Ag | |
GB1324469A (en) | 1970-10-28 | 1973-07-25 | Knoll Ag | Derivatives of benzodiazepines |
ZA7469B (en) | 1973-01-16 | 1974-11-27 | J Voorhees | Compositions and treatment of proliferative skin diseases with-c-amp analogs |
JPS59112984A (ja) | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | 1,4−ベンゾジアゼピン誘導体 |
US4551480A (en) | 1983-06-21 | 1985-11-05 | Stiefel Laboratories, Inc. | Compositions for the treatment of psoriasis |
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
US5004741A (en) * | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
DE3435974A1 (de) * | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung |
FR2591596B1 (fr) | 1985-12-13 | 1988-09-09 | Roussel Uclaf | Nouvelles 4h-triazolo(4,3-a)(1,4)benzodiazepines, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
US4970207A (en) | 1988-07-07 | 1990-11-13 | Fujisawa Pharmaceutical Company, Ltd. | Benzodiazepine derivatives |
US5258510A (en) | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
DE69123090D1 (de) | 1990-07-06 | 1996-12-19 | Yoshitomi Pharmaceutical | Kondensierte Thiophenverbindungen und deren Verwendung |
BR9200951A (pt) | 1991-03-21 | 1992-11-17 | Hoffmann La Roche | Compostos, processo para sua producao,preparacoes farmaceuticas e uso |
GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
US5391566A (en) * | 1993-07-20 | 1995-02-21 | Merck & Co., Inc. | Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives |
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US5444092A (en) | 1994-07-20 | 1995-08-22 | Collins; Jerry | Method and composition for treating psoriasis |
EP0804425A2 (en) * | 1994-07-29 | 1997-11-05 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
EP0776203A4 (en) * | 1994-08-18 | 1997-12-29 | Merck & Co Inc | N-2,3-DIHYDRO-1- (2-PROPYL) -2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINE |
US5677282A (en) | 1995-06-07 | 1997-10-14 | Proscript, Inc. | Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase |
US5692337A (en) * | 1995-06-07 | 1997-12-02 | Motz, Jr.; Ronald W. | Collapsible plant shelter |
US5962337A (en) | 1995-06-29 | 1999-10-05 | Pharmacopeia, Inc. | Combinatorial 1,4-benzodiazepin-2,5-dione library |
RU2096044C1 (ru) | 1995-07-19 | 1997-11-20 | Малое предприятие "Ветта" | Ветеринарный имплантируемый препарат для регулирования биологического ритма животных |
US5929069A (en) | 1995-09-21 | 1999-07-27 | Institute Of Medicinal Molecular Design, Inc. | Compounds activating pharmacological effects of retinoids |
US6579854B1 (en) | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
US7351421B2 (en) * | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
AU721081B2 (en) | 1996-12-10 | 2000-06-22 | Zeria Pharmaceutical Co., Ltd. | 1,5-benzodiazepine derivatives |
US6074859A (en) | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
ATE423130T1 (de) | 1997-10-08 | 2009-03-15 | Isotechnika Inc | Deuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agenzien |
US6206914B1 (en) | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
US20030044776A1 (en) | 1998-09-25 | 2003-03-06 | James A. Dykens | Compositions and methods for identifying agents that alter mitochondrial permeability transition pores |
US7175953B2 (en) | 1999-04-09 | 2007-02-13 | Institute Fuer Diagnostik Forschung | Short-warp peptide-dye conjugate as contrast agent for optical diagnostic |
US7144880B2 (en) * | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
US7276348B2 (en) | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US20030119029A1 (en) | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US20050113460A1 (en) | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20040176358A1 (en) | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US6524623B1 (en) | 1999-11-12 | 2003-02-25 | Milton Hodosh | Therapeutic compositions and methods of use thereof |
DE60117777T2 (de) | 2000-05-11 | 2006-08-17 | Eastman Chemical Co., Kingsport | Acylierte zyclodextrin guest-inklusion komplexe |
US20020048566A1 (en) | 2000-09-14 | 2002-04-25 | El-Deiry Wafik S. | Modulation of cellular apoptosis and methods for treating cancer |
US20020128208A1 (en) | 2000-12-15 | 2002-09-12 | Snyder James P. | Nonpeptide agonists and antagonists of vasopressin receptors |
AU2002317910B2 (en) * | 2001-06-07 | 2008-06-19 | Via Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
WO2003015703A2 (en) | 2001-08-15 | 2003-02-27 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US6662408B2 (en) * | 2001-09-07 | 2003-12-16 | Otis Elevator Company | Elevator load bearing termination assembly with gripping inserts |
AU2002357137A1 (en) | 2001-12-10 | 2003-06-23 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
WO2003106628A2 (en) | 2002-06-17 | 2003-12-24 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase |
US7150433B2 (en) * | 2002-08-16 | 2006-12-19 | Toyota Motor Sales, U.S.A., Inc. | Aircraft bolster trays |
US20040087489A1 (en) | 2002-11-06 | 2004-05-06 | Antonio Ruiz | Compositions and methods for the treatment of mycobacterial infections |
EP1567161A4 (en) * | 2002-12-03 | 2008-09-03 | Vela Acquisition Corp | PHARMACEUTICAL COMPOSITION OF 1- (3,4-DIMETHOXYPHENYL) -4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND ITS USE |
JP2007500212A (ja) * | 2003-05-01 | 2007-01-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 新規化合物およびその標的に関する組成物および方法 |
US7351241B2 (en) | 2003-06-02 | 2008-04-01 | Carl Zeiss Meditec Ag | Method and apparatus for precision working of material |
US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20050272723A1 (en) | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20060052369A1 (en) | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20080314334A1 (en) | 2004-11-10 | 2008-12-25 | Garden Guardian, Inc. | Device and Method for Controlling Animal Behavior |
EP1845996A4 (en) | 2005-01-03 | 2009-04-29 | Univ Michigan | COMPOSITIONS AND METHODS RELATING TO NEW COMPOUNDS AND TARGETS |
WO2007053193A2 (en) | 2005-06-01 | 2007-05-10 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
EP1742460A1 (en) | 2005-06-18 | 2007-01-10 | TTE Germany GmbH | Raster distortion correction circuit |
US20070105844A1 (en) | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
AU2006306347A1 (en) | 2005-10-26 | 2007-05-03 | The Regents Of The University Of Michigan | Therapeutic compositions and methods |
CA2628193C (en) | 2005-11-01 | 2012-08-14 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US7759338B2 (en) | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
MX2008015488A (es) | 2006-06-09 | 2009-02-12 | Univ Michigan | Composiciones y metodos relacionados con compuestos novedosos y objetivos de los mismos. |
GB0615068D0 (en) | 2006-07-28 | 2006-09-06 | Ttp Communications Ltd | Digital radio systems |
MX2009009645A (es) * | 2007-03-09 | 2009-11-19 | Univ Michigan | Composiciones y metodos relacionados con nuevos compuestos y objetivos de los mismos. |
-
2006
- 2006-06-01 WO PCT/US2006/021561 patent/WO2007053193A2/en active Application Filing
- 2006-06-01 EP EP06844130A patent/EP1893218A4/en not_active Withdrawn
- 2006-06-01 JP JP2008514925A patent/JP2008545757A/ja active Pending
- 2006-06-01 AU AU2006309291A patent/AU2006309291B2/en not_active Ceased
- 2006-06-01 CA CA002611031A patent/CA2611031A1/en not_active Abandoned
- 2006-06-01 US US11/445,010 patent/US20070043033A1/en not_active Abandoned
-
2007
- 2007-12-02 IL IL187821A patent/IL187821A0/en unknown
-
2009
- 2009-05-27 US US12/473,144 patent/US7994313B2/en not_active Expired - Fee Related
-
2010
- 2010-08-26 AU AU2010214675A patent/AU2010214675B2/en not_active Ceased
-
2011
- 2011-07-21 US US13/188,234 patent/US20120077805A1/en not_active Abandoned
Patent Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3384635A (en) * | 1966-09-28 | 1968-05-21 | Sterling Drug Inc | 1, 4-benzodiazepine derivatives |
US3415814A (en) * | 1966-09-28 | 1968-12-10 | Sterling Drug Inc | 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione |
US3621828A (en) * | 1968-10-21 | 1971-11-23 | Ib Schreiner Hansen | Target projecting device with magazine indexing mechanism |
US4110337A (en) * | 1973-03-09 | 1978-08-29 | Lipha, Lyonnaise Industrielle Pharmaceutique | Triazolobenzodiazepines |
US4076823A (en) * | 1977-08-18 | 1978-02-28 | E. R. Squibb & Sons, Inc. | Triazolo-2,4-benzodiazepines |
US4495101A (en) * | 1983-04-28 | 1985-01-22 | American Home Products Corporation | Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives |
US4751223A (en) * | 1986-10-14 | 1988-06-14 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines |
US4898861A (en) * | 1987-03-26 | 1990-02-06 | Hoffmann-La Roche Inc. | Method for inhibiting the proliferation of tumor cells |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5041438A (en) * | 1989-10-30 | 1991-08-20 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with benzodiazepine compounds |
US5324726A (en) * | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5597915A (en) * | 1992-03-16 | 1997-01-28 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
US5591227A (en) * | 1992-03-19 | 1997-01-07 | Medtronic, Inc. | Drug eluting stent |
US5599352A (en) * | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
US5697967A (en) * | 1992-03-19 | 1997-12-16 | Medtronic, Inc. | Drug eluting stent |
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
US5861380A (en) * | 1994-11-21 | 1999-01-19 | Cortech, Inc. | Serine protease inhibitors-keto and di-keto containing ring systems |
US20010016583A1 (en) * | 1995-05-18 | 2001-08-23 | Gary D. Glick | Therapeutic application of pro-apoptotic benzodiazepines |
US6080588A (en) * | 1995-05-18 | 2000-06-27 | The Regents Of The University Of Michigan | Therapeutic methods for benzodiazepine derivatives |
US5776946A (en) * | 1995-08-28 | 1998-07-07 | Mcgeer; Patrick L. | Peripheral benzodiazepine receptor ligands as antiinflammatory agents |
US6004942A (en) * | 1995-08-30 | 1999-12-21 | The Regents Of The University Of California | Methods for treating arthritis by administering an apoptosis regulator |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
US6319931B1 (en) * | 1998-06-22 | 2001-11-20 | Centre National De Al Recherche Scientifique (Cnrs) | Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy |
US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
US6767533B1 (en) * | 1998-11-17 | 2004-07-27 | Sanofi-Synthelabo | Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
US6506744B1 (en) * | 1999-07-13 | 2003-01-14 | Hoffmann-La Roche Inc. | Benzazepinone-derivatives |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090012065A1 (en) * | 1999-04-30 | 2009-01-08 | Glick Gary D | Therapeutic applications of pro-apoptotic benzodiazepines |
US8809323B2 (en) | 1999-04-30 | 2014-08-19 | The Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
US20070036854A1 (en) * | 1999-04-30 | 2007-02-15 | Glick Gary D | Therapeutic applications of pro-apoptotic benzodiazepines |
US7638624B2 (en) | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
US7994313B2 (en) | 2005-06-01 | 2011-08-09 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
US8791104B2 (en) | 2005-11-01 | 2014-07-29 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US8088759B2 (en) | 2005-11-01 | 2012-01-03 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US20080064686A1 (en) * | 2006-04-27 | 2008-03-13 | The Regents Of The University Of Michigan | Novel soluble 1,4 benzodiazepine compounds and stable salts thereof |
US7759338B2 (en) | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
US8097612B2 (en) | 2006-06-09 | 2012-01-17 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US8242109B2 (en) | 2007-03-09 | 2012-08-14 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7851465B2 (en) | 2007-03-09 | 2010-12-14 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US8324258B2 (en) | 2007-09-14 | 2012-12-04 | The Regents Of The University Of Michigan | F1F0-ATPase inhibitors and related methods |
US7923486B2 (en) * | 2007-10-04 | 2011-04-12 | Board Of Regents, The University Of Texas System | Bio-polymer and scaffold-sheet method for tissue engineering |
US20090093565A1 (en) * | 2007-10-04 | 2009-04-09 | Board Of Regents, The University Of Texas System | Bio-polymer and scaffold-sheet method for tissue engineering |
US8461153B2 (en) | 2007-11-06 | 2013-06-11 | The Regents Of The University Of Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions |
US8759340B2 (en) | 2007-11-06 | 2014-06-24 | The Regents Of The University Of Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions |
US8188072B2 (en) | 2007-11-06 | 2012-05-29 | The Regents Of The University Of Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions |
US8497307B2 (en) | 2008-09-11 | 2013-07-30 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
US8604023B2 (en) | 2009-04-17 | 2013-12-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
US8673897B2 (en) | 2009-09-18 | 2014-03-18 | The Regents Of The University Of Michigan | Benzodiazepinone compounds and methods of treatment using same |
US8815845B2 (en) | 2009-11-17 | 2014-08-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
US9849138B2 (en) | 2009-11-17 | 2017-12-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties |
Also Published As
Publication number | Publication date |
---|---|
JP2008545757A (ja) | 2008-12-18 |
EP1893218A4 (en) | 2011-01-12 |
CA2611031A1 (en) | 2007-05-10 |
US20090253686A1 (en) | 2009-10-08 |
IL187821A0 (en) | 2008-08-07 |
EP1893218A2 (en) | 2008-03-05 |
AU2010214675B2 (en) | 2011-07-28 |
WO2007053193A2 (en) | 2007-05-10 |
US7994313B2 (en) | 2011-08-09 |
AU2006309291B2 (en) | 2010-05-27 |
AU2010214675A1 (en) | 2010-09-16 |
US20120077805A1 (en) | 2012-03-29 |
WO2007053193A3 (en) | 2007-11-01 |
AU2006309291A1 (en) | 2007-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7994313B2 (en) | Unsolvated benzodiazepine compositions and methods | |
AU2005282461C1 (en) | Compositions and methods relating to novel compounds and targets thereof | |
US7638624B2 (en) | Compositions and methods relating to novel benzodiazepine compounds and derivatives | |
US20060052369A1 (en) | Compositions and methods relating to novel compounds and targets thereof | |
US7759338B2 (en) | Soluble 1,4 benzodiazepine compounds and stable salts thereof | |
AU2005323519B2 (en) | Methods and compositions for treating diseases and conditions associated with mitochondrial function | |
US7276348B2 (en) | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof | |
CA2524394C (en) | Novel benzodiazepine compounds, compositions and uses thereof | |
CA2572962A1 (en) | Compositions and methods relating to novel compounds and targets thereof | |
AU2011244864A1 (en) | Unsolvated benzodiazepine compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF MICHIGAN, THE, MICHIG Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GLICK, GARY D.;MATZGER, ADAM;REEL/FRAME:018250/0802 Effective date: 20060808 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF MICHIGAN;REEL/FRAME:021572/0724 Effective date: 20060725 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |